Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2022-11-02 Capital/Financing Update
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Notice Under Section 708A 1 page 164.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 3 November 2022, titled 'Notice Under Section 708A(5) of the Corporations Act 2001'. It details the issuance of shares by Imugene Limited without disclosure under Part 6D.2 of the Corporations Act, compliance with relevant sections of the Corporations Act, and confirms no excluded information needs to be disclosed. The content is a formal regulatory notice about share issuance and compliance, not a full financial report or detailed analysis. The document length is short (1477 characters), and it serves as a regulatory announcement rather than a report or presentation. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2022-11-02 English
First patient dosed in VAXINIA intratumoral cohort 2 3 pages 235.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 31 October 2022 from Imugene Limited about the dosing of the first patient in a Phase 1 clinical trial cohort. It provides an update on the progress of a clinical trial, describing the trial's purpose, status, and some background information about the company and its pipeline. There are no financial statements, detailed financial analysis, or regulatory filings such as annual or quarterly reports. The document is relatively short (4445 characters) and serves as a progress update rather than a full report. It is not a call transcript, earnings release, or management report. It is clearly an announcement related to clinical trial progress, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-10-30 English
Quarterly Activities/Appendix 4C Cash Flow Report 13 pages 616.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities & Appendix 4C Cash Report' and is an ASX announcement for the quarter ended 30 September 2022. It contains detailed operational updates, clinical trial progress, management appointments, financial updates including cash flow and cash position, and a quarterly cash flow report (Appendix 4C). The content includes substantive financial data such as net cash used in operating activities and cash on hand, as well as business activities during the quarter. This matches the characteristics of an Interim / Quarterly Report (IR), which provides comprehensive financial and operational information for a period shorter than a full fiscal year. The document is not merely an announcement of a report but contains actual financial and operational data. Therefore, the correct classification is IR. Q1 2023
2022-10-27 English
Application for quotation of securities - IMU 8 pages 29.7KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, and classifications of quoted and unquoted securities. There is no financial performance data, management discussion, or regulatory certification. The document is clearly an announcement related to capital changes, specifically the issuance and quotation of new shares following option exercises. This fits the definition of a Share Issue/Capital Change announcement rather than a full financial report or other categories.
2022-10-26 English
Application for quotation of securities - IMU 8 pages 29.7KB
Share Issue/Capital Change Classification · 95% confidence The document is an application for quotation of securities on the ASX (Australian Securities Exchange) for Imugene Limited. It details the issuance and conversion of options into ordinary fully paid shares, the number of securities to be quoted, issue dates, and other related information. There is no financial performance data, earnings information, management discussion, or regulatory certification. The document is an announcement related to capital changes, specifically the issuance and quotation of new shares resulting from option exercises. This fits the category of Share Issue/Capital Change (SHA). The document length is 6640 characters, which is sufficient to contain substantive details about the share issuance rather than a brief notice. Therefore, the appropriate classification is SHA with high confidence.
2022-10-20 English
Release of Shares from Escrow 1 page 134.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement regarding the release of shares from escrow, referencing ASX listing rule 3.10A. It is a brief regulatory announcement about share capital status, not a financial report or detailed filing. The document length is short (590 characters), and it does not contain financial statements or detailed analysis. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-10-18 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.